Silence Therapeutics plc (SLNCF)
USD 0.95
(90.53%)
USD 0.95
(90.53%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 25.37 Million GBP | 44.99% |
| 2022 | 17.5 Million GBP | 40.97% |
| 2021 | 12.41 Million GBP | 126.59% |
| 2020 | 5.47 Million GBP | 2145.49% |
| 2019 | 244 Thousand GBP | 0.0% |
| 2018 | - GBP | -100.0% |
| 2017 | 16 Thousand GBP | -97.92% |
| 2016 | 770 Thousand GBP | 0.0% |
| 2015 | - GBP | -100.0% |
| 2014 | 15 Thousand GBP | -87.18% |
| 2013 | 117 Thousand GBP | -28.22% |
| 2012 | 163 Thousand GBP | -76.51% |
| 2011 | 694 Thousand GBP | -70.67% |
| 2010 | 2.36 Million GBP | 37.32% |
| 2009 | 1.72 Million GBP | -22.0% |
| 2008 | 2.2 Million GBP | -45.42% |
| 2007 | 4.04 Million GBP | 107.86% |
| 2006 | 1.94 Million GBP | 282.51% |
| 2005 | 509 Thousand GBP | 220.13% |
| 2004 | 159 Thousand GBP | -88.18% |
| 2003 | 1.34 Million GBP | 16.85% |
| 2002 | 1.15 Million GBP | 734.06% |
| 2001 | 138 Thousand GBP | -85.61% |
| 2000 | 959 Thousand GBP | -30.0% |
| 1999 | 1.37 Million GBP | 552.38% |
| 1998 | 210 Thousand GBP | 0.0% |
| 1997 | - GBP | 0.0% |
| 1996 | - GBP | 0.0% |
| 1995 | - GBP | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 598 Thousand GBP | -95.18% |
| 2024 Q1 | 12.4 Million GBP | 491.04% |
| 2023 FY | 25.37 Million GBP | 44.99% |
| 2023 Q2 | 9.1 Million GBP | -19.96% |
| 2023 Q4 | 2.09 Million GBP | -24.98% |
| 2023 Q1 | 11.37 Million GBP | 138.7% |
| 2023 Q3 | 2.79 Million GBP | -69.27% |
| 2022 FY | 17.5 Million GBP | 40.97% |
| 2022 Q2 | 3.64 Million GBP | -36.33% |
| 2022 Q3 | 3.37 Million GBP | -7.47% |
| 2022 Q1 | 5.72 Million GBP | 67.6% |
| 2022 Q4 | 4.76 Million GBP | 41.35% |
| 2021 Q2 | 2.7 Million GBP | -14.09% |
| 2021 FY | 12.41 Million GBP | 126.59% |
| 2021 Q1 | 3.14 Million GBP | 34.07% |
| 2021 Q3 | 3.15 Million GBP | 16.85% |
| 2021 Q4 | 3.41 Million GBP | 8.17% |
| 2020 Q2 | 573 Thousand GBP | 0.0% |
| 2020 FY | 5.47 Million GBP | 2145.49% |
| 2020 Q1 | 573 Thousand GBP | 369.67% |
| 2020 Q3 | 1.98 Million GBP | 246.95% |
| 2020 Q4 | 2.34 Million GBP | 17.96% |
| 2019 Q1 | - GBP | 0.0% |
| 2019 FY | 244 Thousand GBP | 0.0% |
| 2019 Q2 | - GBP | 0.0% |
| 2019 Q3 | 122 Thousand GBP | 0.0% |
| 2019 Q4 | 122 Thousand GBP | 0.0% |
| 2018 Q1 | - GBP | 0.0% |
| 2018 Q3 | - GBP | 0.0% |
| 2018 Q2 | - GBP | 0.0% |
| 2018 FY | - GBP | -100.0% |
| 2018 Q4 | - GBP | 0.0% |
| 2017 Q3 | - GBP | -100.0% |
| 2017 Q1 | 8000.00 GBP | -97.92% |
| 2017 Q2 | 8000.00 GBP | 0.0% |
| 2017 Q4 | - GBP | 0.0% |
| 2017 FY | 16 Thousand GBP | -97.92% |
| 2016 Q3 | 385 Thousand GBP | 0.0% |
| 2016 FY | 770 Thousand GBP | 0.0% |
| 2016 Q1 | - GBP | 0.0% |
| 2016 Q2 | - GBP | 0.0% |
| 2016 Q4 | 385 Thousand GBP | 0.0% |
| 2015 Q1 | - GBP | -100.0% |
| 2015 Q2 | - GBP | 0.0% |
| 2015 Q4 | - GBP | 0.0% |
| 2015 Q3 | - GBP | 0.0% |
| 2015 FY | - GBP | -100.0% |
| 2014 FY | 15 Thousand GBP | -87.18% |
| 2014 Q4 | 4000.00 GBP | 0.0% |
| 2014 Q3 | 4000.00 GBP | 14.29% |
| 2014 Q2 | 3500.00 GBP | 0.0% |
| 2014 Q1 | 3500.00 GBP | -90.79% |
| 2013 FY | 117 Thousand GBP | -28.22% |
| 2013 Q4 | 38 Thousand GBP | 0.0% |
| 2013 Q1 | 20.5 Thousand GBP | 0.0% |
| 2013 Q2 | 20.5 Thousand GBP | 0.0% |
| 2013 Q3 | 38 Thousand GBP | 85.37% |
| 2012 Q2 | - GBP | 0.0% |
| 2012 FY | 163 Thousand GBP | -76.51% |
| 2011 FY | 694 Thousand GBP | -70.67% |
| 2011 Q2 | - GBP | 0.0% |
| 2010 Q2 | - GBP | 0.0% |
| 2010 FY | 2.36 Million GBP | 37.32% |
| 2009 FY | 1.72 Million GBP | -22.0% |
| 2009 Q2 | - GBP | 0.0% |
| 2008 Q2 | - GBP | 0.0% |
| 2008 FY | 2.2 Million GBP | -45.42% |
| 2007 FY | 4.04 Million GBP | 107.86% |
| 2007 Q2 | - GBP | 0.0% |
| 2006 FY | 1.94 Million GBP | 282.51% |
| 2006 Q2 | - GBP | 0.0% |
| 2005 FY | 509 Thousand GBP | 220.13% |
| 2005 Q2 | - GBP | 0.0% |
| 2004 Q2 | - GBP | 0.0% |
| 2004 FY | 159 Thousand GBP | -88.18% |
| 2003 FY | 1.34 Million GBP | 16.85% |
| 2003 Q2 | - GBP | 0.0% |
| 2002 FY | 1.15 Million GBP | 734.06% |
| 2001 FY | 138 Thousand GBP | -85.61% |
| 2000 FY | 959 Thousand GBP | -30.0% |
| 1999 FY | 1.37 Million GBP | 552.38% |
| 1998 FY | 210 Thousand GBP | 0.0% |
| 1997 FY | - GBP | 0.0% |
| 1996 FY | - GBP | 0.0% |
| 1995 FY | - GBP | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Capstone Therapeutics Corp. | 48.35 Million USD | 47.522% |
| Skye Bioscience, Inc. | - USD | -Infinity% |
| Santhera Pharmaceuticals Holding AG | 122.95 Million USD | 79.362% |
| Nascent Biotech, Inc. | - USD | -Infinity% |
| Qrons Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 16.68 Million USD | -52.079% |
| CSL Limited | 14.69 Billion USD | 99.827% |
| Evofem Biosciences, Inc. | 18.21 Million USD | -39.285% |
| Arch Therapeutics, Inc. | 75.72 Thousand USD | -33409.852% |
| Regen BioPharma, Inc. | 236.56 Thousand USD | -10626.666% |
| Northwest Biotherapeutics, Inc. | 1.93 Million USD | -1213.406% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | 658.5 Thousand USD | -3753.455% |
| Eiger BioPharmaceuticals, Inc. | 15.77 Million USD | -60.876% |
| Nanobac Pharmaceuticals, Incorporated | 17.62 Thousand USD | -143904.313% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| SQZ Biotechnologies Company | 21.47 Million USD | -18.144% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | -38506.074% |
| Propanc Biopharma, Inc. | - USD | -Infinity% |
| Mesoblast Limited | 5.9 Million USD | -329.939% |
| Marizyme, Inc. | 645.81 Thousand USD | -3829.174% |
| Genus plc | 668.8 Million USD | 96.206% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| Pharming Group N.V. | 245.31 Million USD | 89.656% |
| Therapeutic Solutions International, Inc. | 98.99 Thousand USD | -25532.867% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | -6086.535% |
| Nymox Pharmaceutical Corporation | - USD | -Infinity% |
| ContraFect Corporation | - USD | -Infinity% |
| PsyBio Therapeutics Corp. | - USD | -Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | -32957.151% |
| IMV Inc. | - USD | -Infinity% |
| AXIM Biotechnologies, Inc. | 39.51 Thousand USD | -64111.246% |
| MultiCell Technologies, Inc. | 49.32 USD | -51449616.139% |
| ONE Bio Corp. | 52.29 Million USD | 51.478% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 49.72 Million USD | 48.965% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 48.9 Thousand USD | -51791.616% |
| Q BioMed Inc. | 284.35 Thousand USD | -8823.799% |
| Emmaus Life Sciences, Inc. | 29.59 Million USD | 14.265% |
| Mosaic ImmunoEngineering Inc. | - USD | -Infinity% |
| Biomind Labs Inc. | - USD | -Infinity% |
| American Oriental Bioengineering, Inc. | 145.09 Million USD | 82.512% |
| Provectus Biopharmaceuticals, Inc. | 557.71 Thousand USD | -4449.856% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | -36150.0% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | - USD | -Infinity% |
| Curative Biotechnology, Inc. | - USD | -Infinity% |
| GB Sciences, Inc. | - USD | -Infinity% |
| Alpha Cognition Inc. | - USD | -Infinity% |
| HST Global, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Halberd Corporation | 999.00 USD | -2539940.04% |
| Enzolytics Inc. | 52.79 Thousand USD | -47962.353% |
| Agentix Corp. | - USD | -Infinity% |
| Resverlogix Corp. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 608.52 Thousand USD | -4069.919% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.22 Billion USD | 97.931% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | 140.24 Thousand USD | -17993.724% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | -4010.084% |
| Zenith Capital Corp. | - USD | -Infinity% |
| Genscript Biotech Corporation | 839.52 Million USD | 96.977% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | - USD | -Infinity% |
| WPD Pharmaceuticals Inc. | - USD | -Infinity% |
| Cotinga Pharmaceuticals Inc. | - USD | -Infinity% |
| Kadimastem Ltd | - USD | -Infinity% |
| Helix BioMedix, Inc. | 997.72 Thousand USD | -2443.283% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | - USD | -Infinity% |
| LadRx Corporation | - USD | -Infinity% |
| Cell Source, Inc. | - USD | -Infinity% |
| Regen BioPharma, Inc. | 236.56 Thousand USD | -10626.666% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Affymax, Inc. | 1.36 Million USD | -1753.543% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | - USD | -Infinity% |
| CytoDyn Inc. | - USD | -Infinity% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 473.73 Thousand USD | -5256.427% |
| SYBLEU INC | 11.69 Thousand USD | -216854.514% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | -Infinity% |
| International Stem Cell Corporation | 7.78 Million USD | -225.78% |
| Bioxytran, Inc. | - USD | -Infinity% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 13 Thousand USD | -195092.308% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | - USD | -Infinity% |
| Neutra Corp. | 39.53 Thousand USD | -64085.258% |
| Windtree Therapeutics, Inc. | - USD | -Infinity% |
| PureTech Health plc | 3.33 Million USD | -662.012% |
| Coeptis Therapeutics, Inc. | - USD | -Infinity% |
| IXICO plc | 6.66 Million USD | -280.72% |
| IntelGenx Technologies Corp. | 1.03 Million USD | -2342.252% |
| Gelesis Holdings, Inc. | 25.76 Million USD | 1.521% |
| CSL Limited | 14.8 Billion USD | 99.829% |
| Cellectis S.A. | 755 Thousand USD | -3260.927% |